A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial
Robert K. Mahar,
Anna McGlothlin,
Michael Dymock,
Todd C. Lee,
Roger J. Lewis,
Thomas Lumley,
Jocelyn Mora,
David J. Price,
Benjamin R. Saville,
Tom Snelling,
Rebecca Turner,
Steven A. Webb,
Joshua S. Davis,
Steven Y. C. Tong,
Julie A. Marsh,
on behalf of the SNAP Global Trial Steering Committee
Affiliations
Robert K. Mahar
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne
Anna McGlothlin
Berry Consultants LLC
Michael Dymock
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute
Todd C. Lee
Division of Infectious Diseases, Department of Medicine, McGill University
Roger J. Lewis
Berry Consultants LLC
Thomas Lumley
Department of Statistics, University of Auckland
Jocelyn Mora
Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity
David J. Price
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne
Benjamin R. Saville
Berry Consultants LLC
Tom Snelling
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute
Rebecca Turner
Medical Research Council Clinical Trials Unit at University College London
Steven A. Webb
St John of God Healthcare
Joshua S. Davis
Department of Infectious Diseases, John Hunter Hospital
Steven Y. C. Tong
Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity
Julie A. Marsh
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute
on behalf of the SNAP Global Trial Steering Committee
Abstract The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is a multifactorial Bayesian adaptive platform trial that aims to improve the way that S. aureus bloodstream infection, a globally common and severe infectious disease, is treated. In a world first, the SNAP trial will simultaneously investigate the effects of multiple intervention modalities within multiple groups of participants with different forms of S. aureus bloodstream infection. Here, we formalise the trial structure, modelling approach, and decision rules that will be used for the SNAP trial. By summarising the statistical principles governing the design, our hope is that the SNAP trial will serve as an adaptable template that can be used to improve comparative effectiveness research efficiency in other disease areas. Trial registration NCT05137119 . Registered on 30 November 2021.
